Search results
Showing 1051 to 1065 of 1516 results for patients and public
The geko device for reducing the risk of venous thromboembolism (HTG344)
Evidence-based recommendations on the geko device for reducing the risk of venous thromboembolism.
Macular translocation with 360° retinotomy for wet age-related macular degeneration (HTG216)
Evidence-based recommendations on macular translocation with 360° retinotomy for wet age-related macular degeneration. This involves cutting and moving the macula on to a nearby healthier area of the choroid layer.
In development Reference number: GID-IPG10448 Expected publication date: 15 October 2026
Inebilizumab for treating AQP4-IgG-seropositive neuromyelitis optica spectrum disorders [ID6430]
Awaiting development Reference number: GID-TA11530 Expected publication date: TBC
Tislelizumab with chemotherapy for untreated advanced oesophageal squamous cell cancer [ID5113]
In development Reference number: GID-TA11025 Expected publication date: TBC
Evidence-based recommendations on exagamglogene autotemcel (Casgevy) for transfusion-dependent beta-thalassaemia in people 12 years and over.
This guideline covers identifying and treating primary hypertension (high blood pressure) in people aged 18 and over, including people with type 2 diabetes. It aims to reduce the risk of cardiovascular problems such as heart attacks and strokes by helping healthcare professionals to diagnose hypertension accurately and treat it effectively.
Elosulfase alfa for treating mucopolysaccharidosis type 4A (HST19)
Evidence-based recommendations on elosulfase alfa (Vimizim) for treating mucopolysaccharidosis type 4A in people of all ages.
Evidence-based recommendations on total wrist replacement. This involves creating an artificial wrist joint consisting of metal implants attached to the end of the arm and to the hand, separated by a spacer to allow movement.
View recommendations for HTG173Show all sections
Sections for HTG173
Evidence standards framework (ESF) for digital health technologies
NICE standards for innovators of digital health technologies and NHS commissioners
Larotrectinib for treating NTRK fusion-positive solid tumours (TA630)
Evidence-based recommendations on larotrectinib (Vitrakvi) for treating neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours in adults and children.
NICE public committee meetings supports our commitment to having processes in place that are rigorous, open, and transparent.
NICE public committee meetings supports our commitment to having processes in place that are rigorous, open, and transparent.
Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma (TA524)
Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating CD30-positive Hodgkin lymphoma in adults.
Digital technologies to support smoking cessation in secondary care patients: early value assessment
In development Reference number: GID-HTE10061 Expected publication date: TBC